Amylyx price target raised to $4 from $3 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Amylyx to $4 from $3 and keeps a Neutral rating on the shares. The firm cites the company’s acquisition of Phase 3-ready avexitide from Eiger as announced yesterday and contends that the deal for a “relatively de-risked” asset builds Amylyx’s late-stage pipeline, even though much remains to be understood regarding the market opportunity, including in the context of GLP-1RAs and other anti-obesity medications which may disrupt the rate of bariatric surgeries over the medium to long-term, the analyst tells investors in a research note.